Microfluidics Q&A

Q&A based on the presentation Detection and Characterization of Viral Pathogens and Their Impact on the Immune System by Bill Hunt, MS, Director, Microfluidics Product Management at Fluidigm.

As researchers around the world mount an aggressive and sustained response to the COVID-19 pandemic, it is important to build on past successes and harness insights from current efforts to better detect and characterize pathogens, identify treatments, and prepare for future outbreaks. Fluidigm microfluidics-based genomic analysis tools can support and accelerate these goals by leveraging the benefits of nanoliter-scale automated microfluidics technology.